Genetic translocations and the risk for more aggressive forms of prostate cancer

A research group at Memorial Sloan-Kettering Cancer Center has published data indicating that translocation and/or deletion of the  TMPRSS2-ERG fusion gene  — which occurs in about 50 percent of the cases of clinically localized prostate cancer — is not, in fact, a prognostic indicator of risk for a more aggressive type of disease. … READ MORE …

Gene fusions and prostate cancer

According to a report in the Washington Post earlier today, based on a letter to the editor published in Nature, researchers at the University of Michigan have shown that gene fusion (a process in which selected DNA sequences fuse together when their chromosomes trade places with each other) can occur in prostate cancer. … READ MORE …